These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22844394)

  • 1. Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer.
    Rafii A; Stoeckle E; Jean-Laurent M; Ferron G; Morice P; Houvenaeghel G; Lecuru F; Leblanc E; Querleu D
    PLoS One; 2012; 7(7):e39415. PubMed ID: 22844394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-operative pancreatic fistula following splenectomy with or without distal pancreatectomy at cytoreductive surgery in advanced ovarian cancer.
    Bizzarri N; Korompelis P; Ghirardi V; O'Donnell RL; Rundle S; Naik R
    Int J Gynecol Cancer; 2020 Jul; 30(7):1043-1051. PubMed ID: 32546641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.
    Liberale G; Pop CF; Polastro L; Kerger J; Moreau M; Chintinne M; Larsimont D; Nogaret JM; Veys I
    J Visc Surg; 2020 Apr; 157(2):79-86. PubMed ID: 31837942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
    Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
    Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
    Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.
    Todo Y; Sakuragi N; Oikawa M; Negishi H; Yamamoto R; Yoshiaki K; Tsumura N; Kawaguchi I; Fujimoto S
    Int J Clin Oncol; 2003 Apr; 8(2):90-6. PubMed ID: 12720101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer.
    Bacalbasa N; Balescu I; Balalau C; Ionescu O; Stoica C
    In Vivo; 2018; 32(2):431-436. PubMed ID: 29475933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity.
    Long KC; Tanner EJ; Frey M; Leitao MM; Levine DA; Gardner GJ; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2013 Dec; 131(3):525-30. PubMed ID: 24016410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.
    Benedetti Panici P; Di Donato V; Fischetti M; Casorelli A; Perniola G; Musella A; Marchetti C; Palaia I; Berloco P; Muzii L
    Gynecol Oncol; 2015 Jun; 137(3):406-11. PubMed ID: 25824857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
    Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"?
    Ceccaroni M; Roviglione G; Bruni F; Clarizia R; Ruffo G; Salgarello M; Peiretti M; Uccella S
    Surg Endosc; 2018 Apr; 32(4):2026-2037. PubMed ID: 29052073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Filippova OT; Chi DS; Long Roche K; Sonoda Y; Zivanovic O; Gardner GJ; Tew WP; O'Cearbhaill R; Sarraf S; Sun SW; Alexander K; Korc-Grodzicki B; Shahrokni A
    Gynecol Oncol; 2019 Jul; 154(1):77-82. PubMed ID: 31078241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.